A carregar...
ANGI-10. WSD1227: A BRAIN PENETRABLE VEGFR2 INHIBITOR FOR THE TREATMENT OF PRIMARY AND METASTATIC BRAIN TUMORS
The VEGF pathway has emerged as an important target for cancer therapy by blocking the development of malignant neovasculature, thus to reduce oxygen availability to the tumor and decrease its growth. Anti-VEGF agents have been approved for several malignancies, such as GBM, NSCLC, mBC, CRC, OC, etc...
Na minha lista:
| Publicado no: | Neuro Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6217140/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.111 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|